Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Longboard Pharmaceuticals (LBPH)
NASDAQ:LBPH
RESEARCH TOOLSreports
Longboard Pharmaceuticals (LBPH) Stock Price & Analysis
191 Followers
LBPH Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$3.60 - $28.15
Previous Close$21.7
Volume139.39K
Average Volume (3M)508.08K
Market Cap
$843.70M
Enterprise Value$795.67M
Total Cash (Recent Filing)$48.50M
Total Debt (Recent Filing)$475.00K
Price to Earnings (P/E)-9.6
Beta0.06
Next Earnings
Aug 01, 2024EPS Estimate
-$0.44Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.26
Shares Outstanding38,880,054
10 Day Avg. Volume341,045
30 Day Avg. Volume508,081
Standard Deviation0.50
R-Squared0.02
Alpha0.06
Financial Highlights & Ratios
Price to Book (P/B)20.94
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-19.40
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-14.48
Forecast
1Y Price Target
$42.50Price Target Upside93.27% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
Longboard Pharmaceuticals News
PremiumCompany Announcements
Longboard Pharmaceuticals to Reveal Bexicaserin Study Results
Bulls Say, Bears Say
Bulls Say
Clinical Trial ProgressComplete PACIFIC enrollment and 100% patient continuation into the open-label extension indicates strong interest and potential for LP352.
Drug DevelopmentLP352, a first-in-class 5-HT2C receptor superagonist, has the potential to be a disruptive next generation therapy for developmental and epileptic encephalopathies.
Regulatory Milestone AnticipationAnticipation of a positive outcome from discussions with the FDA and other regulatory agencies, which can further de-risk the program.
Bears Say
Clinical Trial OutcomesIn recent clinical trials, participants using the drug reported serious adverse events while no such events were reported in the placebo group, suggesting potential safety issues.
Drug Safety ConcernsThe drug’s limited adoption can likely be attributed to historical potential concerns surrounding its toxicity, such as cardiotoxicity.
Financial PerformanceLBPH reported a quarterly loss greater than analysts had estimated, which could indicate financial instability or underperformance.
---
Ownership Overview
0.10% Insiders
19.55% Mutual Funds
13.40% Other Institutional Investors
66.95% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
LBPH FAQ
What was Longboard Pharmaceuticals’s price range in the past 12 months?
Longboard Pharmaceuticals lowest stock price was $3.60 and its highest was $28.15 in the past 12 months.
What is Longboard Pharmaceuticals’s market cap?
Currently, no data Available
When is Longboard Pharmaceuticals’s upcoming earnings report date?
Longboard Pharmaceuticals’s upcoming earnings report date is Aug 01, 2024 which is in 83 days.
How were Longboard Pharmaceuticals’s earnings last quarter?
Longboard Pharmaceuticals released its earnings results on May 02, 2024. The company reported -$0.42 earnings per share for the quarter, beating the consensus estimate of -$0.491 by $0.071.
Is Longboard Pharmaceuticals overvalued?
According to Wall Street analysts Longboard Pharmaceuticals’s price is currently Undervalued.
Does Longboard Pharmaceuticals pay dividends?
Longboard Pharmaceuticals does not currently pay dividends.
What is Longboard Pharmaceuticals’s EPS estimate?
Longboard Pharmaceuticals’s EPS estimate is -$0.44.
How many shares outstanding does Longboard Pharmaceuticals have?
Longboard Pharmaceuticals has 33,609,300 shares outstanding.
What happened to Longboard Pharmaceuticals’s price movement after its last earnings report?
Longboard Pharmaceuticals reported an EPS of -$0.42 in its last earnings report, beating expectations of -$0.491. Following the earnings report the stock price went down -6.269%.
Which hedge fund is a major shareholder of Longboard Pharmaceuticals?
Among the largest hedge funds holding Longboard Pharmaceuticals’s share is Farallon Capital Management, L.L.C.. It holds Longboard Pharmaceuticals’s shares valued at 9M.
---
Longboard Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$42.50 (93.27% Upside)
$42.50 (93.27% Upside)
Blogger Sentiment
Neutral
LBPH Sentiment 50%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 41.0 Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days <0.1%
Last 30 Days ▼ 7.7%
Last 30 Days ▼ 7.7%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
131.83%
12-Months-Change
Fundamentals
Return on Equity
-30.04%
Trailing 12-Months
Asset Growth
311.21%
Trailing 12-Months
Company Description
Longboard Pharmaceuticals
Longboard Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases. Its pipeline includes LP352, LP143, and LP659.
---
LBPH Earnings Call
Q4 2023
0:00 / 0:00
---
LBPH Stock 12 Month Forecast
Average Price Target
$42.50
▲(93.27% Upside)
Technical Analysis
Sarepta Therapeutics
―
Ultragenyx Pharmaceutical
―
Aldeyra Therapeutics
―
Agios Pharma
―
Best Analysts Covering LBPH
1 Year
1 Year Success Rate
14/16 ratings generated profit
1 Year Average Return
+115.97%
reiterated a buy rating 3 days ago
Copying Patrick Trucchio's trades and holding each position for 1 Year would result in 87.50% of your transactions generating a profit, with an average return of +115.97% per trade.
---